Characteristics | Values |
---|---|
Male | 365 (46.3) |
Age (years) | 39 ± 8.6 |
Route of transmission (N = 775) | |
Heterosexual | 740 (95.5) |
Homosexual | 27 (3.5) |
IVDU | 5 (0.6) |
Unknown | 3 (0.4) |
Race (Thai) | 764 (97.0) |
Baseline body weight (kilograms) (N = 628) | 54.4 ± 10.4 |
Residential area (Urban area) | 597 (82.3) |
Health insurance (N = 777) | |
No | 46 (5.9) |
Government fund | 142 (18.3) |
Social security fund | 418 (53.8) |
Global Fund for AIDS, TB, Malaria | 171 (22.0) |
Combination antiretroviral therapy (cART) | |
Nevirapine-based | 657 (83.4) |
Efavirenz-based | 117 (14.8) |
Protease inhibitor-based | 8 (1.0) |
Zidovudine/lamivudine/abacavir | 6 (0.8) |
Opportunistic infections (OIs) (N = 782) | 490 (62.7) |
OIs before cART | 434 (55.5) |
Tuberculosis | 198 (25.3) |
Adherence ≥ 95% | 754 (95.7) |
Laboratory findings | |
Baseline CD4 cell counts (median, IQR) (cells/mm3) | 57.7 (22, 127) |
Baseline CD4 cell counts < 100 cells/mm3 | 525 (66.6) |
Baseline CD4 cell counts 100-199 cells/mm3 | 195 (24.7) |
Baseline CD4 cell counts ≥ 200 cells/mm3 | 68 (8.7) |
Baseline Hemoglobin level (mg/dL) | 11.2 ± 1.9 |
Positive anti-HCV antibody (N = 599) | 61(10.2) |
Positive HBs-antigen (N = 608) | 66 (10.9) |